Last reviewed · How we verify
DE-117 and 0.0015% tafluprost
DE-117 and 0.0015% tafluprost is a Small molecule drug developed by Santen Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | DE-117 and 0.0015% tafluprost |
|---|---|
| Sponsor | Santen Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-117 and 0.0015% tafluprost CI brief — competitive landscape report
- DE-117 and 0.0015% tafluprost updates RSS · CI watch RSS
- Santen Inc. portfolio CI
Frequently asked questions about DE-117 and 0.0015% tafluprost
What is DE-117 and 0.0015% tafluprost?
DE-117 and 0.0015% tafluprost is a Small molecule drug developed by Santen Inc..
Who makes DE-117 and 0.0015% tafluprost?
DE-117 and 0.0015% tafluprost is developed by Santen Inc. (see full Santen Inc. pipeline at /company/santen-inc).
What development phase is DE-117 and 0.0015% tafluprost in?
DE-117 and 0.0015% tafluprost is in Phase 1.
Related
- Manufacturer: Santen Inc. — full pipeline
- Compare: DE-117 and 0.0015% tafluprost vs similar drugs
- Pricing: DE-117 and 0.0015% tafluprost cost, discount & access